Anti-thrombotic regimens for patients with Atrial fibrillation following PCI: a new era

Anti-thrombotic regimens for patients with Atrial fibrillation following PCI: a new era

Video On Demand

Thursday 24th May 2018 @ 14:15 CEST
LIVE from euroPCR 2018

Faculty: Prof. Georg Nickenig (Bonn, Germany) & Dr Jur ten Berg (Utrecht, Netherlands)

 

Join Professor Nickenig and Dr Berg live from Paris as they discuss the latest data presented at euroPCR on anti-thrombotic regimens for patients with Atrial fibrillation following PCI, and how it may impact clinical practice.

Faculty:

Professor Georg Nickenig, Medical Clinic and PolyClinic II, Bonn University, Bonn, Germany
Prof. Georg Nickenig is Full Professor and Chair, Department of Internal Medicine and Polyclinic II, University Hospital Bonn, Germany. He completed his doctoral degree in Clinical Medicine from University of Bonn, Germany. Prof Nickenig has been awarded with different honors such as Albert Fraenkel Prize of the German Society of Cardiology, Theodor Frerichs - Award of the German Society of Internal Medicine, etc. He has been an active author of many papers and book publications. He is also the editorial board member and reviewer of many Journals.

 

Dr Jur ten Berg, St. Antonius Hospital, Nieuwegein, Utrecht, Netherlands
Dr Berg focuses on Interventional Cardiology after completing his training as a cardiologist at St. Antonius Hospital in 1996. He obtained his doctorate at the University of Nijmegen in 2001, and is an active author of many papers.

This live stream is to inform and educate on:

  • New data released at euroPCR on anti-thrombotic regimens for patients with Atrial fibrillation following PCI
  • Dual vs. triple therapy and considerations for different patient sub-groups including ACS vs non-ACS, drug-eluting vs. stents, and renal function
  • How new data may impact clinical practice or current guidelines
  • Cardiologists
  • Interventional Cardiologists
  • Electrophysiologists

 

 

This interview is funded through an unrestricted educational grant by Boehringer Ingelheim.